Thyroid hormone β receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys

British Journal of Pharmacology

Volumn 156, Issue 3, 2009, Pages 454-465

  Ito, B R ^a   Zhang, B H ^a   Cable, E E ^a   Song, X ^a   Fujitaki, J M ^a   MacKenna, D A ^a   Wilker, C E ^a   Chi, B ^a   Van Poelje, P D ^a   Linemeyer, D L ^a   Erion, M D ^a  

^a Metabasis Therapeutics Inc   (United States)

Author keywords

Hyperlipidaemia; LDL cholesterol; Statins; Thyroid receptor agonists

Indexed keywords

3,5 DIMETHYL 4 (4' HYDROXY 3' ISOPROPYLBENZYL)PHENOXYMETHYLPHOSPHONIC ACID; ATORVASTATIN; CHOLESTEROL; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN RECEPTOR; MB 07344; MB 07811; THYROID HORMONE RECEPTOR AGONIST; THYROID HORMONE RECEPTOR BETA; THYROXINE; UNCLASSIFIED DRUG; 2 ((3,5 DIMETHYL 4 (4' HYDROXY 3' ISOPROPYLBENZYL)PHENOXY)METHYL) 4 (3 CHLOROPHENYL) 2 OXIDO(1,3,2)DIOXAPHOSPHONANE; 2-((3,5-DIMETHYL-4-(4'-HYDROXY-3'-ISOPROPYLBENZYL)PHENOXY)METHYL)-4-(3-CHLOROPHENYL)-2-OXIDO(1,3,2)DIOXAPHOSPHONANE; 3,5 DIMETHYL 4 (4' HYDROXY 3' ISOPROPYLBENZYL)PHENOXY METHYLPHOSPHONIC ACID; 3,5-DIMETHYL-4-(4'-HYDROXY-3'-ISOPROPYLBENZYL)PHENOXY METHYLPHOSPHONIC ACID; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PHENOL DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PRODRUG; PYRROLE DERIVATIVE;

ADD ON THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOG; DRUG EFFICACY; FEMALE; HYPERLIPIDEMIA; MALE; MONKEY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RABBIT; ANIMAL; BLOOD; DOSE RESPONSE; DRUG COMBINATION; DRUG POTENTIATION; HYPERCHOLESTEROLEMIA; MACACA;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HYPERCHOLESTEROLEMIA; MACACA FASCICULARIS; MALE; PHENOLS; PHOSPHONIC ACIDS; PRODRUGS; PYRROLES; RABBITS; THYROID HORMONE RECEPTORS BETA;

EID: 65449171996     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2009.00038.x     Document Type: Article

References (48)

1. Abrams JJ, Grundy SM (1981). Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J Lipid Res 22 : 323 338.
2. Aikawa M, Libby P (2000). Lipid lowering reduces proteolytic and prothrombotic potential in rabbit atheroma. Ann N Y Acad Sci 902 : 140 152.
3. Alegret M, Verd JC, Diaz C, Hernandez G, Adzet T, Sanchez RM et al. (1998). Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits. Eur J Pharmacol 347 : 283 291.
4. Bakker O, Hudig F, Meijssen S, Wiersinga WM (1998). Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun 249 : 517 521.
5. Berkenstam A, Kristensen J, Mellstrom K, Carlsson B, Malm J, Rehnmark S et al. (2008). The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 105 : 663 667.
6. Bocan TM (1998). Animal models of atherosclerosis and interpretation of drug intervention studies. Curr Pharm Des 4 : 37 52.
7. Bocan TM, Krause BR, Rosebury WS, Lu X, Dagle C, Bak Mueller S et al. (2001). The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression. Atherosclerosis 157 : 97 105.
8. Bolayirli IM, Aslan M, Balci H, Altug T, Hacibekiroglu M, Seven A (2007). Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci 81 : 121 127.
9. Chiang JY (2004). Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 40 : 539 551.
10. Davidson MH, Toth PP (2004). Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 47 : 73 104.
11. Davis HR Jr., Pula KK, Alton KB, Burrier RE, Watkins RW (2001). The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 50 : 1234 1241.
12. Denke MA (2004). Coadministration of multidrug therapy to achieve lipid goals. J Am Osteopath Assoc 104 : S17 22.
13. Erion MD, Reddy KR, Boyer SH, Matelich MC, Gomez-Galeno J, Lemus RH et al. (2004). Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J Am Chem Soc 126 : 5154 5163.
14. Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD et al. (2007). Targeting thyroid hormone receptor-{beta} agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 104 : 15490 15495.
15. Goldstein JL, Brown MS (1990). Regulation of the mevalonate pathway. Nature 343 : 425 430.
16. Grover GJ, Mellstrom K, Ye L, Malm J, Li YL, Bladh LG et al. (2003). Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 100 : 10067 10072.
17. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr., Clark LT, Hunninghake DB et al. (2004). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 : 227 239.
18. Gullberg H, Rudling M, Salto C, Forrest D, Angelin B, Vennstrom B (2002). Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice. Mol Endocrinol 16 : 1767 1777.
19. Gylling H, Miettinen TA (2002). Inheritance of cholesterol metabolism of probands with high or low cholesterol absorption. J Lipid Res 43 : 1472 1476.
20. Hoenig MR, Kostner KM, Read SJ, Walker PJ, Atherton JJ (2007). Implications of the obesity epidemic for statin therapy: shifting cholesterol metabolism to a high synthesis and low dietary absorption state. Endocr Metab Immune Disord Drug Targets 7 : 153 166.
21. Horton JD, Cuthbert JA, Spady DK (1995). Regulation of hepatic 7 alpha-hydroxylase expression and response to dietary cholesterol in the rat and hamster. J Biol Chem 270 : 5381 5387.
22. Horton JD, Goldstein JL, Brown MS (2002). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 : 1125 1131.
23. Hylemon PB, Gurley EC, Stravitz RT, Litz JS, Pandak WM, Chiang JY et al. (1992). Hormonal regulation of cholesterol 7 alpha-hydroxylase mRNA levels and transcriptional activity in primary rat hepatocyte cultures. J Biol Chem 267 : 16866 16871.
24. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA et al. (2000). Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 28 : 1369 1378.
25. Jelinek DF, Andersson S, Slaughter CA, Russell DW (1990). Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis. J Biol Chem 265 : 8190 8197.
26. Johansson L, Rudling M, Scanlan TS, Lundasen T, Webb P, Baxter J et al. (2005). Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA 102 : 10297 10302.
27. Jones MP, Pandak WM, Heuman DM, Chiang JY, Hylemon PB, Vlahcevic ZR (1993). Cholesterol 7 alpha-hydroxylase: evidence for transcriptional regulation by cholesterol or metabolic products of cholesterol in the rat. J Lipid Res 34 : 885 892.
28. Lopez D, Abisambra Socarras JF, Bedi M, Ness GC (2007). Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim Biophys Acta 1771 (9 1216 1225.
29. Morkin E, Ladenson P, Goldman S, Adamson C (2004). Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. J Mol Cell Cardiol 37 : 1137 1146.
30. National Cholesterol Education Panel. NHLBI NIoH (2002). The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circ Res 106 : 3413 3421.
31. Ness GC, Lopez D (1995). Transcriptional regulation of rat hepatic low-density lipoprotein receptor and cholesterol 7 alpha hydroxylase by thyroid hormone. Arch Biochem Biophys 323 : 404 408.
32. Ness GC, Lopez D, Chambers CM, Newsome WP, Cornelius P, Long CA et al. (1998). Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression. Biochem Pharmacol 56 : 121 129.
33. Pandak WM, Heuman DM, Hylemon PB, Vlahcevic ZR (1990). Regulation of bile acid synthesis. IV. Interrelationship between cholesterol and bile acid biosynthesis pathways. J Lipid Res 31 : 79 90.
34. Pandak WM, Heuman DM, Redford K, Stravitz RT, Chiang JY, Hylemon PB et al. (1997). Hormonal regulation of cholesterol 7alpha-hydroxylase specific activity, mRNA levels, and transcriptional activity in vivo in the rat. J Lipid Res 38 : 2483 2491.
35. Pantos C, Mourouzis I, Paizis I, Malliopoulou V, Xinaris C, Moraitis P et al. (2007). Pharmacological inhibition of TRalpha1 receptor potentiates the thyroxine effect on body weight reduction in rats: potential therapeutic implications in controlling body weight. Diabetes Obes Metab 9 : 136 138.
36. Pearson TA, Laurora I, Chu H, Kafonek S (2000). The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 : 459 467.
37. Qin W, Infante J, Wang SR, Infante R (1992). Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Biochim Biophys Acta 1127 : 57 66.
38. Rashid S, Uffelman KD, Barrett PH, Lewis GF (2002). Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit. Circulation 106 : 2955 2960.
39. Ratliff EP, Gutierrez A, Davis RA (2006). Transgenic expression of CYP7A1 in LDL receptor-deficient mice blocks diet-induced hypercholesterolemia. J Lipid Res 47 : 1513 1520.
40. Rudel L, Deckelman C, Wilson M, Scobey M, Anderson R (1994). Dietary cholesterol and downregulation of cholesterol 7 alpha-hydroxylase and cholesterol absorption in African green monkeys. J Clin Invest 93 : 2463 2472. (Pubitemid 24177160)
41. Sample CE, Pendleton LC, Ness GC (1987). Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels by L-triiodothyronine. Biochemistry 26 : 727 731.
42. Shin DJ, Osborne TF (2003). Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2). J Biol Chem 278 : 34114 34118.
43. Slater EE, MacDonald JS (1988). Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs 36 (Suppl. 3 72 82.
44. Staels B, Van Tol A, Chan L, Will H, Verhoeven G, Auwerx J (1990). Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low density lipoprotein receptor in rats. Endocrinology 127 : 1144 1152.
45. Vlahcevic ZR, Heuman DM, Hylemon PB (1991). Regulation of bile acid synthesis. Hepatology 13 : 590 600.
46. Xu G, Salen G, Shefer S, Ness GC, Nguyen LB, Parker TS et al. (1995). Unexpected inhibition of cholesterol 7 alpha-hydroxylase by cholesterol in New Zealand white and Watanabe heritable hyperlipidemic rabbits. J Clin Invest 95 : 1497 1504.
47. Xu G, Salen G, Shefer S, Ness GC, Nguyen LB, Tint GS et al. (1996). Increasing hepatic cholesterol 7alpha-hydroxylase reduces plasma cholesterol concentrations in normocholesterolemic and hypercholesterolemic rabbits. Hepatology 24 : 882 887.
48. Yen PM (2001). Physiological and molecular basis of thyroid hormone action. Physiol Rev 81 : 1097 1142.